Assessment of hepatitis B virus relapse in cancer patients receiving chemotherapy with prophylactic nucleos(t)ide analogues: Implications for overall mortality.
Chih-Wen WangChung-Feng HuangMing-Lun YehPo-Cheng LiangTyng-Yuang JangYu-Ju WeiPo-Yau HsuMing-Yen HsiehYi-Hung LinJee-Fu HuangChia-Yen DaiWan-Long ChuangMing-Lung YuPublished in: Liver international : official journal of the International Association for the Study of the Liver (2024)
The risk of virological and clinical relapse was linked to baseline HBV DNA, end-of-treatment HBsAg levels and TDF or TAF for prophylaxis; additionally, experiencing relapse heightens the risk of all-cause mortality. Further research is warranted to explore potential strategies for preventing virological and clinical relapse in high-risk patients.
Keyphrases
- hepatitis b virus
- free survival
- liver failure
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- antiretroviral therapy
- hiv infected patients
- type diabetes
- papillary thyroid
- cardiovascular events
- risk factors
- squamous cell carcinoma
- risk assessment
- single molecule
- molecular docking
- cardiovascular disease
- cell free
- squamous cell
- coronary artery disease
- lymph node metastasis
- circulating tumor cells